• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Idarucizumab for urgent reversal of dabigatran for heart transplant: A case report.

作者信息

Rimsans Jessica, Rhoten Megan, Sylvester Katelyn, Singh Steve K, Connors Jean M

机构信息

Department of Pharmacy Services, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Division of Cardiac Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

出版信息

Am J Hematol. 2017 Mar;92(3):E34-E35. doi: 10.1002/ajh.24638. Epub 2017 Feb 1.

DOI:10.1002/ajh.24638
PMID:28033655
Abstract
摘要

相似文献

1
Idarucizumab for urgent reversal of dabigatran for heart transplant: A case report.艾达西珠单抗用于心脏移植中达比加群的紧急逆转：一例报告。
Am J Hematol. 2017 Mar;92(3):E34-E35. doi: 10.1002/ajh.24638. Epub 2017 Feb 1.
2
Idarucizumab for the reversal of dabigatran in patients undergoing heart transplantation.艾达司珠单抗用于心脏移植患者中达比加群的逆转。
Eur J Heart Fail. 2019 Jan;21(1):129-131. doi: 10.1002/ejhf.1356. Epub 2018 Dec 6.
3
Idarucizumab for Dabigatran Reversal Guideline.
Crit Pathw Cardiol. 2016 Jun;15(2):33-5. doi: 10.1097/HPC.0000000000000074.
4
Intravenous stroke thrombolysis after reversal of dabigatran effect by idarucizumab: first reported case in Hong Kong.达比加群效应被依达赛珠单抗逆转后进行静脉溶栓治疗：香港首例报告病例。
Hong Kong Med J. 2018 Feb;24(1):81-3. doi: 10.12809/hkmj166231.
5
Idarucizumab for Reversal of Dabigatran Prior to Acute Surgery: A Schematic Approach Based on a Case Report.艾达司珠单抗用于急性手术前达比加群的逆转：基于病例报告的示意性方法
Basic Clin Pharmacol Toxicol. 2017 Apr;120(4):407-410. doi: 10.1111/bcpt.12696. Epub 2016 Dec 16.
6
Reversal of dabigatran with idarucizumab in hyperacute stroke: a new paradigm?
Med J Aust. 2019 Apr;210(7):302-303.e1. doi: 10.5694/mja2.50122. Epub 2019 Mar 29.
7
Reversal of dabigatran by idarucizumab: when and how?依达鲁单抗逆转达比加群：何时及如何逆转？
Expert Rev Hematol. 2016 Jun;9(6):519-28. doi: 10.1080/17474086.2016.1184569.
8
Repeated Administration of Idarucizumab to a Patient with Dabigatran Overdose.达比加群酯过量患者重复给予依达鲁单抗。
Hamostaseologie. 2018 Feb;38(1):39-42. doi: 10.5482/HAMO-17-03-0015. Epub 2018 Feb 26.
9
Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran.关注艾达司珠单抗及其逆转达比加群抗凝作用的潜力。
Drug Des Devel Ther. 2016 May 18;10:1683-9. doi: 10.2147/DDDT.S94167. eCollection 2016.
10
Interpretation of idarucizumab clinical trial data based on spontaneous reports of dabigatran adverse effects in the French pharmacovigilance database.基于法国药物警戒数据库中达比加群不良反应自发报告对依达赛珠单抗临床试验数据的解读。
Thromb Res. 2016 Oct;146:43-45. doi: 10.1016/j.thromres.2016.08.014. Epub 2016 Aug 24.

引用本文的文献

1
Idarucizumab (Praxbind) for dabigatran reversal in patients undergoing heart transplantation: a cohort of ten patients.依达赛珠单抗（Praxbind）用于心脏移植患者达比加群的逆转：十例患者队列研究
Future Sci OA. 2021 Feb 15;7(4):FSO689. doi: 10.2144/fsoa-2020-0186.
2
Use of Idarucizumab to Revert the Anticoagulant Effect of Dabigatran in Heart Transplant Surgery: An Institutional Experience.艾达凝血酶原复合物用于逆转达比加群在心脏移植手术中的抗凝作用：一项机构经验。
Case Rep Cardiol. 2020 Mar 6;2020:6927423. doi: 10.1155/2020/6927423. eCollection 2020.
3
Two Dabigatran Fast Reversals in a 4-month Period - a Case Report.
4个月内两次达比加群快速逆转——病例报告
Eur J Case Rep Intern Med. 2019 Dec 4;6(12):001311. doi: 10.12890/2019_001311. eCollection 2019.
4
Evidence for Idarucizumab (Praxbind) in the Reversal Of the Direct Thrombin Inhibitor Dabigatran: Review Following the RE-VERSE AD Full Cohort Analysis.艾达赛珠单抗（Praxbind）逆转直接凝血酶抑制剂达比加群作用的证据：RE-VERSE AD全队列分析后的综述
P T. 2017 Nov;42(11):692-698.
5
Dabigatran reversal with idarucizumab in a patient undergoing heart transplantation: first European report.依达赛珠单抗用于心脏移植患者达比加群逆转：首例欧洲报告
Thromb J. 2017 Sep 5;15:23. doi: 10.1186/s12959-017-0147-z. eCollection 2017.